Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
Christian Diego Rolfo, Philip C. Mack, Giorgio V. Scagliotti et al. · Journal of Thoracic Oncology · 2021
Cited by 676 works. doi:10.1016/j.jtho.2021.06.017
Authors
- Christian Diego Rolfo
- Philip C. Mack
- Giorgio V. Scagliotti
- Charu Aggarwal
- Maria E. Arcila
- Fabrice Barlési
- Trever Grant Bivona
- Maximilian Diehn
- Caroline Dive
- Rafał Dziadziuszko
- Natasha B. Leighl
- Umberto Malapelle
- Tony S.K. Mok
- Nir Peled
- Luis Estuardo Raez
- Lecia Van Dam Sequist
- Lynette Marie Sholl
- Charles Swanton
- Christopher Abbosh
- Daniel S.W. Tan
References
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- OncoKB: A Precision Oncology Knowledge Base